In the context of non-small cell lung carcinoma (NSCLC), statin administration has been reported to attenuate PD-L1 surface expression and trigger ferroptotic cell death pathways, thereby potentially constraining tumoural aggressiveness and metastatic competence [267]. The gene discussed is CD274; the disease is neoplasm.